{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:48:37Z","timestamp":1793213317456,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":691,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002387","name":"National Cancer Institute, Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jtct.2021.04.002","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:25:24Z","timestamp":1618964724000},"page":"571-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hematopoietic Stem Cell Transplantation in T Cell and Natural Killer Cell Lymphomas: Update on Recent Advances"],"prefix":"10.1016","volume":"27","author":[{"given":"Yang Liang","family":"Boo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Piu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jtct.2021.04.002_bib0001","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","article-title":"Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995","volume":"92","author":"Groves","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"10.1016\/j.jtct.2021.04.002_bib0002","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"Project IT-CL. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.04.002_bib0003","series-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev. 4th ed. Vol. 2","article-title":"Extranodal NK\/T-cell lymphoma, nasal type","author":"Chan","year":"2017"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0004","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2141.1997.1462962.x","article-title":"CD56+ NK lymphomas: clinicopathological features and prognosis","volume":"97","author":"Kwong","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2021.04.002_bib0005","series-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev. 4th ed. Vol. 2","article-title":"Mycosis fungoides","author":"Cerroni","year":"2017"},{"key":"10.1016\/j.jtct.2021.04.002_bib0006","series-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues. Rev. 4th ed. Vol. 2","article-title":"Sezery syndrome","author":"Whittaker","year":"2017"},{"key":"10.1016\/j.jtct.2021.04.002_bib0007","unstructured":"Zain J, Thomas SH. Hematopoietic cell transplantation for non-Hodgkin Lymphoma (T cell). In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. John Wiley & Sons."},{"issue":"suppl 5","key":"10.1016\/j.jtct.2021.04.002_bib0008","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2021.04.002_bib0010","unstructured":"Schmitz N, Nickelsen M, Altmann B, et\u00a0al. Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial. 2015;33(15)(suppl):8507."},{"issue":"25","key":"10.1016\/j.jtct.2021.04.002_bib0011","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2021.04.002_bib0012","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","article-title":"Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control","volume":"52","author":"Zain","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2021.04.002_bib0013","first-page":"1512","article-title":"Outcome of patients with gamma delta T cell lymphomas: analysis of 1429 cases registered in the Prospective T-Cell Project","volume":"130","author":"Foss","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0015","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","article-title":"Natural killer-cell malignancies: diagnosis and treatment","volume":"19","author":"Kwong","year":"2005","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.jtct.2021.04.002_bib0016","first-page":"4997","article-title":"How I treat NK\/T-cell lymphomas","volume":"121","author":"Tse","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2021.04.002_bib0017","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0018","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"issue":"33","key":"10.1016\/j.jtct.2021.04.002_bib0019","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.jtct.2021.04.002_bib0020","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0021","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2021.04.002_bib0023","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.002_bib0024","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/cncr.26629","article-title":"Phase 2 trial of \u2018sandwich\u2019 L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma","volume":"118","author":"Jiang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2021.04.002_bib0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","article-title":"First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0026","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0027","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bmt.1705349","article-title":"High-dose chemotherapy with autologous stem cell transplantation in extranodal NK\/T-cell lymphoma: a retrospective comparison with non-transplantation cases","volume":"37","author":"Kim","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0028","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdg458","article-title":"Autologous stem cell transplantation for nasal NK\/T-cell lymphoma: a progress report on its value","volume":"14","author":"Au","year":"2003","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0029","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705244","article-title":"Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms","volume":"37","author":"Suzuki","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bmt.1700606","article-title":"Autologous bone marrow transplantation for primary nasal T\/NK cell lymphoma","volume":"19","author":"Liang","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0031","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12185-017-2324-z","article-title":"Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma, nasal type: a retrospective controlled study in a single center","volume":"107","author":"Wang","year":"2018","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0033","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation","volume":"56","author":"Fox","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0034","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-014-2171-4","article-title":"Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0036","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0037","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.bbmt.2018.07.034","article-title":"Allogeneic stem cell transplantation for patients with natural killer\/T cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation","volume":"24","author":"Jeong","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0038","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2021.04.002_bib0039","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0041","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jtct.2021.04.002_bib0042","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2017.01.082","article-title":"Allogeneic hematopoietic cell transplantation for aggressive NK cell leukemia: a Center for International Blood and Marrow Transplant Research analysis","volume":"23","author":"Hamadani","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-020-01009-8","article-title":"Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia","volume":"56","author":"Fujimoto","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0044","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood.V112.11.774.774","article-title":"Patients with mature T-cell lymphoma show high relapse rates after high dose therapy and autologous stem cell transplantation","volume":"112","author":"Nickelsen","year":"2008","journal-title":"Blood"},{"issue":"15)(suppl","key":"10.1016\/j.jtct.2021.04.002_bib0045","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1200\/jco.2011.29.15_suppl.6565","article-title":"Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): the University of Texas MD Anderson Cancer Center (MDACC) experience","volume":"29","author":"Beitinjaneh","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2021.04.002_bib0046","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hon.63_2629","article-title":"Autologous stem cell transplantation as part of first-line therapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"37","author":"Lopez-Parra","year":"2019","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0047","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/10428194.2017.1300888","article-title":"Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study","volume":"58","author":"Cederleuf","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0048","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.24372","article-title":"Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas","volume":"91","author":"Yam","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0049","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7150\/ijms.23067","article-title":"Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas","volume":"15","author":"Wu","year":"2018","journal-title":"Int J Med Sci"},{"issue":"3","key":"10.1016\/j.jtct.2021.04.002_bib0050","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0051","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-018-3288-7","article-title":"The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience","volume":"97","author":"Rohlfing","year":"2018","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2021.04.002_bib0052","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1080\/10428194.2018.1563691","article-title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","volume":"60","author":"Al-Mansour","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0053","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2021.04.002_bib0054","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-138700","article-title":"Autologous stem cell transplantation (ASCT) for T-cell lymphoma (T-NHL) patients who achieve complete (CR1) or partial remission (PR1) with first-line treatment: a systematic review and meta-analysis","volume":"136","author":"Koh","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0055","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0056","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0057","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12185-020-02879-w","article-title":"Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"112","author":"Yamasaki","year":"2020","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2021.04.002_bib0058","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2021.04.002_bib0059","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jtct.2021.04.002_bib0060","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0061","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.002_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0063","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/annonc\/mdu515","article-title":"Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center","volume":"26","author":"Loirat","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2021.04.002_bib0064","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41409-018-0417-9","article-title":"Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas","volume":"54","author":"Mussetti","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0065","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2021.04.002_bib0066","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41409-018-0360-9","article-title":"Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease","volume":"54","author":"Wulf","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2021.04.002_bib0067","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0068","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","article-title":"Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma","volume":"19","author":"Czajczynska","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2021.04.002_bib0069","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0070","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood-2004-02-0545","article-title":"Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities","volume":"104","author":"Sorror","year":"2004","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.jtct.2021.04.002_bib0071","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a European Society for Blood and Marrow Transplantation Lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2021.04.002_bib0072","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0073","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2021.04.002_bib0074","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2021.04.002_bib0075","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2021.04.002_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2021.04.002_bib0077","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2021.04.002_bib0078","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic \u03b3\u03b4 T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2021.04.002_bib0079","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1038\/bcj.2015.43","article-title":"Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma","volume":"5","author":"Rashidi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2021.04.002_bib0080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.jtct.2021.04.002_bib0081","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Lymphoma Working Committee of the CIBMTR. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2021.04.002_bib0082","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0083","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","article-title":"Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant","volume":"6","author":"Ghosh","year":"2020","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2021.04.002_bib0084","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2021.04.002_bib0085","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2021.04.002_bib0086","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0087","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2021.04.002_bib0088","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41409-020-01133-5","article-title":"Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome","volume":"56","author":"Castagna","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2021.04.002_bib0089","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","article-title":"Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy","volume":"105","author":"Barker","year":"2005","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2021.04.002_bib0090","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0091","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2017.10.040","article-title":"Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia","volume":"24","author":"Hsu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.002_bib0092","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3324\/haematol.2015.138594","article-title":"Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival","volume":"101","author":"van Besien","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2021.04.002_bib0093","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.bbmt.2020.07.032","article-title":"Impact of donor source on allogeneic hematopoietic stem cell transplantation for mature T cell and natural killer cell neoplasms in the Kyoto Stem Cell Transplantation Group","volume":"26","author":"Watanabe","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.002_bib0094","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2013.088997","article-title":"Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood","volume":"99","author":"Rodrigues","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2021.04.002_bib0096","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/bmt.2014.259","article-title":"Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor","volume":"50","author":"Bachanova","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0097","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of pretransplantation 18f-fluorodeoxy glucose\u2013positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.002_bib0098","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/bmt.2014.211","article-title":"Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT","volume":"50","author":"Bachanova","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.002_bib0099","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020008825","article-title":"A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL","author":"Shmitz","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2021.04.002_bib0100","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.bbmt.2017.04.021","article-title":"Outcome of allogeneic and autologous hematopoietic cell transplantation for high-risk peripheral T cell lymphomas: a retrospective analysis from a Chinese center","volume":"23","author":"Huang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2021.04.002_bib0101","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:40Z","timestamp":1763002840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721008265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2666636721008265"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Stem Cell Transplantation in T Cell and Natural Killer Cell Lymphomas: Update on Recent Advances","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}